Autor(es)Abdallah Al-Ola,Herlopian Aline,Ravilla Rahul,Bansal Meghana,Chandra-Reddy Sowmya,Mahmoud Fade,Ong Shirley,Gokden Murat,Hutchins Laura

ResumoIpilimumab is a novel humanized monoclonal antibody directed against cytotoxic T lymphocyte antigen 4, a T-cell surface molecule involved in down-regulation and suppression of the T cell response to stimuli. Patients treated with ipilimumab are at risk for immune-related adverse events involving the skin, digestive tract, liver and endocrine organs. Few case reports of immune-related adverse effects involving central or peripheral nervous system due to ipilimumab are published. These include inflammatory myopathy, aseptic meningitis, severe meningo-radiculo-neuritis, temporal arteritis, Guillain-Barre syndrome, and posterior reversible encephalopathy syndrome. We report the first case of ipilimumab-induced progressive necrotic myelopathy.

Palavras-ChaveIpilimumab, immune-related adverse events, progressive necrotic myelopathy

ImprentaJournal of Oncology Pharmacy Practice, 2015

DescritoresGuillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Immune response

Data de Publicação:2015